Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesElectrocore LLC

Electrocore LLC

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
7.25 USD -0.04 ( 0.55%)
Last update at 2026-11-06T21:00:00Z
VOLUME
129034
Market Cap
90.61M

Momentum Score

…

electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.25
Low
8.93
High
52 Week Price Range
4.41
Low
10.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

ElectroCore makes a non-invasive vagus nerve stimulation device for primary headache disorders such as cluster headache and migraine. Long-term growth may be supported by expanding clinical evidence, broader international rollout and greater clinician adoption of neuromodulation. The company appears positioned in a niche with potential for recurring device and service revenue if uptake continues.
Material risks include limited commercial traction and scale, dependence on payer coverage and clinician acceptance, competition from other neuromodulation and pharmaceutical therapies, potential regulatory setbacks and the possibility of needing additional financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
7.29
Dividend Yield
-
Revenue TTM
36.97M
Revenue Per Share
4.14
Gross Profit TTM
32.18M
Debt / Equity
-5.50
ROE
-478.70%
Net Debt
2.37M
ROCE
-179.71%
Diluted EPS TTM
-1.70

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -13.96M -11.98M -19.02M -22.59M -18.07M
Net income -13.97M -11.89M -18.83M -22.16M -17.22M
Selling general administrative 38.21M 31.20M 26.44M 24.33M 21.57M
Gross profit 27.79M 21.40M 13.23M 6.98M 4.07M
Reconciled depreciation 1.68M 1.26M 0.88M 0.55M 0.38M
Ebit -13.15M -12.16M -19.02M -23.42M -20.04M
Ebitda -11.48M -10.90M -17.76M -22.87M -22.01M
Depreciation and amortization 1.68M 1.26M 1.26M 0.55M -1.97M
Operating income -13.15M -12.16M -18.80M -22.87M -20.04M
Other operating expenses 45.19M 37.34M 34.84M 31.47M 25.49M
Interest expense 0.59M 0.39M - 0.29M 4.33M
Tax provision 0.00M -0.09M -0.20M -0.43M -0.85M
Interest income 0.30M 0.57M 0.44M 0.29M 0.01M
Net interest income -0.29M 0.57M 0.44M 0.29M 0.01M
Income tax expense 0.00M -0.09M -0.19M -0.43M -0.85M
Total revenue 32.03M 25.18M 16.03M 8.59M 5.45M
Total operating expenses 40.94M 33.56M 32.03M 29.85M 24.11M
Cost of revenue 4.24M 3.79M 2.80M 1.62M 1.39M
Total other income expense net -0.81M 0.18M -0.21M 0.28M 1.97M
Net income from continuing ops -13.97M -11.89M -20.59M -22.16M -17.22M
Net income applicable to common shares - - - -22.16M -17.22M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 18.67M 20.47M 16.39M 24.76M 42.83M
Other current assets -2.66M 1.29M 0.84M 0.83M 1.05M
Total liab 20.38M 12.93M 8.95M 7.67M 6.18M
Total stockholder equity -1.71M 7.54M 7.44M 17.09M 36.65M
Other current liab 8.26M 6.50M 5.63M 4.69M 3.88M
Common stock 0.01M 0.01M 0.01M 0.01M 0.07M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.07M
Retained earnings -191.06M -177.09M -165.20M -146.37M -124.21M
Other assets - - - 3.46M -0.00M
Cash 7.04M 3.45M 10.58M 17.71M 34.69M
Total current liabilities 11.35M 9.15M 8.12M 7.04M 5.49M
Current deferred revenue - 0.08M 0.24M 0.15M -
Net debt 2.37M 0.69M -9.96M -17.01M -33.93M
Short term debt 0.38M 0.36M 0.09M 0.07M 0.06M
Short long term debt total 9.40M 4.14M 0.63M 0.70M 0.76M
Other stockholder equity 189.24M 184.51M 172.70M 163.52M 160.77M
Property plant equipment - - - 0.61M 0.76M
Total current assets 11.61M 16.30M 14.29M 21.17M 37.54M
Net tangible assets - - - 16.31M 36.13M
Short term investments 4.58M 8.52M - - 0.00M
Net receivables 1.03M 1.37M 0.72M 0.40M 0.44M
Long term debt 6.61M - - - -
Inventory 1.63M 1.68M 2.16M 1.98M 1.36M
Accounts payable 2.71M 1.83M 2.16M 2.13M 1.54M
Accumulated other comprehensive income 0.10M 0.11M -0.06M -0.07M 0.01M
Non currrent assets other 7.06M 0.27M 1.10M 2.97M 4.53M
Non current assets total 7.06M 4.17M 2.09M 3.58M 5.29M
Capital lease obligations 2.80M 4.14M 0.63M 0.70M 0.76M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 3.94M -8.52M -0.17M 0.00M 18.22M
Change to liabilities - - - 1.19M 0.46M
Total cashflows from investing activities 3.88M -8.52M -0.21M - 18.22M
Net borrowings 7.50M 0.00M - - -
Total cash from financing activities 7.63M 8.44M 7.49M 0.00M 25.68M
Change to operating activities - - - 0.52M 1.01M
Net income -13.97M -11.89M -18.83M -22.16M -17.22M
Change in cash 3.33M -6.88M -7.38M -16.73M 30.45M
Begin period cash flow 3.70M 10.58M 17.96M 34.69M 4.24M
End period cash flow 7.04M 3.70M 10.58M 17.96M 34.69M
Total cash from operating activities -8.19M -6.95M -14.67M -16.64M -13.63M
Issuance of capital stock 0.22M 8.30M 8.14M 0.00M 25.68M
Depreciation 1.68M 1.26M 1.02M 0.55M 0.38M
Other cashflows from investing activities - -8.52M - - -
Dividends paid - - 0.00M - -
Change to inventory 0.02M 0.71M 0.10M 0.30M 0.37M
Change to account receivables -0.14M -0.71M -0.26M 0.04M -0.22M
Other cashflows from financing activities 7.63M 0.14M -0.66M - 18.22M
Change to netincome - - - 2.93M 1.58M
Capital expenditures 0.07M 0.00M 0.21M 0.00M 0.00M
Change in working capital 1.32M 1.76M 0.81M 2.04M 1.63M
Stock based compensation 1.93M 1.87M 1.70M 2.68M 3.30M
Other non cash items 0.85M 0.05M 0.63M 0.24M -0.01M
Free cash flow -8.25M -6.95M -14.87M -16.64M -13.63M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ECOR
Electrocore LLC		 -0.04
0.55%		 7.25 - 384.62 2.45 34.88 2.36 0.16
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Electrocore LLC

electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

200 Forge Way, Rockaway, NJ, United States, 07866

888 903 2673

https://www.electrocore.com

83

Name Title Year Born
Mr. Daniel S. Goldberger CEO & Director 1959
Mr. Joseph P. Errico Co-Founder, Principal Investor & Director 1969
Dr. Thomas J. Errico M.D. Founder, Independent Director & Principal Investor 1952
Mr. Brian M. Posner CFO & Corp. Sec. 1962
Mr. Michael Romaniw Exec. VP of Systems & Operations 1957
Ms. Jackie Dorsky VP of Marketing NA
Mr. Iain Strickland Ph.D. Sr. VP of Global Sales & Strategy NA
Ms. Carrie Kochek Sr. Director of HR NA
Dr. Peter S. Staats M.B.A., M.D. Chief Medical Officer 1963
Mr. Eric J. Liebler Sr. VP of Neurology 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…